Volume 8. Article 3. The eggs of Bathygobius soporator (Cuvier and Valenciennes) with a discussion of other non-spherical teleost eggs.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1129/thumbnail.jp

Volume 1. Scientific Results of the First Oceanographic Expedition of the “Pawnee,” 1925. Article 1. Fishes.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1003/thumbnail.jp

Volume 10. Article 2. An analysis of the deceptive resemblances of fishes to plant parts, with critical remarks on protective coloration, mimicry and adaptation.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1137/thumbnail.jp

Volume 6. Article 5. A contribution to the life histories of Atlantic Ocean Flyingfishes.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1120/thumbnail.jp

Volume 2. Scientific Results of the Second Oceanographic Expedition of the “Pawnee,” 1926. Article 1. Elasmobranchii from Panama to Lower California

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1008/thumbnail.jp

Volume 2. Scientific Results of the Second Oceanographic Expedition of the “Pawnee,” 1926. Article 3. Heterosomata to Pediculati from Panama to Lower California.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1010/thumbnail.jp

Volume 2. Scientific Results of the Second Oceanographic Expedition of the “Pawnee,” 1926. Article 2. Nematognathi, Apodes, Isospondyli, Synentognathi, and Thoracostraci from Panama to Lower California. With a generic analysis of the Exocœtidæ.

https://elischolar.library.yale.edu/bulletin_yale_bingham_oceanographic_collection/1009/thumbnail.jp

Effect of short term caffeine supplementation and intermittent exercise on muscle damage markerseffect of short term caffeine supplementation and intermittent exercise on muscle damage markers

Aim: To evaluate the effect of oral caffeine supplementation and strenuous intermittent exercise on muscle damage markers in soccer players. Materials and Methods: 15 male professional soccer players completed a placebo controlled double blind test protocol. At 45 min before exercise, participants ingested 5.5 mg•kg-1 body mass of caffeine (CAF, n=8) or cellulose (CEL, n=7). The exercise was 2 trials of 6 sets of 10 sprints (20 m each) with 10 s recovery time between sprints, 2 min between sets and 15 min between trials. Blood samples were collected before (PRE), 24, 48 and 72 h after exercise. Serum activity of creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransaminase (AST), and alanine aminotrasaminase (ALT) were quantified. Results: Serum enzyme activity was enhanced by exercise in both groups, without a synergistic effect of caffeine. Conclusion: Our results suggest muscle damage markers increases after physical activities, but caffeine supplementation (5.5 mg•kg-1 body mass) has no influence upon serum enzymes reflective of muscle integrity and damage

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

BACKGROUND: Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. METHODS: In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, α-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0·019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0·002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov, NCT03713593, and is active but not recruiting. FINDINGS: Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 66·0 years (IQR 57·0-72·0), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 32·1 months (IQR 29·4-35·3). Median overall survival was 21·2 months (95% CI 19·0-23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2-21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71-1·00; stratified log-rank p=0·023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 8·2 months (95% CI 6·4-8·4; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 8·0 months (6·3-8·2; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 0·87; 95% CI 0·73-1·02; stratified log-rank p=0·047). The most common treatment-related grade 3-4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]). INTERPRETATION: In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. FUNDING: Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck

Population expansion of the invasive Pomacentridae Chromis limbata (Valenciennes, 1833) in Southern Brazilian coast: long-term monitoring, fundamental niche availability and new records

Human-mediated species invasions are recognized as a leading cause of global biotic homogenization and extinction. Studies on colonization events since early stages, establishment of new populations and range extension are scarce because of their rarity, difficult detection and monitoring. Chromis limbata is a reef-associated and non-migratory marine fish from the family Pomacentridae found in depths ranging between 3 and 45 m. The original distribution of the species encompassed exclusively the eastern Atlantic, including the Azores, Madeira and the Canary Islands. It is also commonly reported from West Africa between Senegal and Pointe Noire, Congo. In 2008, vagrant individuals of C. limbata were recorded off the east coast of Santa Catarina Island, South Brazil (27° 41' 44″ S, 48° 27' 53″ W). This study evaluated the increasing densities of C. limbata populations in Santa Catarina State shoreline. Two recent expansions, northwards to São Paulo State and southwards to Rio Grande do Sul State, are discussed, and a niche model of maximum entropy (MaxEnt) was performed to evaluate suitable C. limbata habitats. Brazilian populations are established and significantly increasing in most sites where the species has been detected. The distributional boundaries predicted by the model are clearly wider than their known range of occurrence, evidencing environmental suitability in both hemispheres from areas where the species still does not occur. Ecological processes such as competition, predation and specially habitat selectivity may regulate their populations and overall distribution range. A long-term monitoring programme and population genetics studies are necessary for a better understanding of this invasion and its consequences to natural communities.CNPq, Grant/Award Number: CNPq 475367/2006-5; ECOPERE-SE Project; FAPES, Grant/Award Number: PROFIX program No 10/2018 -T.O.: 348/2018; FAPESC, Grant/Award Number: Biodiversidade Marinha do Estado de Santa Catarina Project PI: A.L. FAPESC 4302/2010-8; FAPESC/CNPq, Grant/Award Number: SISBIOTA-Mar project PI: S.R.F. CNPq 563276/2010-0; FAPESC 6308/2011-8; Petrobras (BR), Grant/Award Number: MAArE Project; King Abdullah University of Science and Technology; Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorinfo:eu-repo/semantics/publishedVersio